(Circulation. 2001;103:1274.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
Long-Term Stable Correction of Low-Density Lipoprotein Receptor–Deficient Mice With a Helper-Dependent Adenoviral Vector Expressing the Very Low-Density Lipoprotein Receptor
From the Departments of Molecular and Cellular Biology (K.O., I.-H.K., A.M., S.N., H.-J.L., M.M.-S., C.A.-R., L.C.), Molecular and Human Genetics (L.P., B.L., A.B.), Pathology (M.F.), and Medicine (L.C.), Baylor College of Medicine, Houston, Texas.
Correspondence to Dr Lawrence Chan, Departments of Molecular and Cellular Biology and Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. E-mail lchan{at}bcm.tmc.edu
Background—Familial
hypercholesterolemia (FH) that results from LDL receptor (LDLR)
deficiency affects 
1 in 500 persons in the heterozygous state
and 1 in 1 million persons in the homozygous state. We tested
a novel gene therapy strategy for the treatment of FH in a mouse
model.
Methods and Results—We
delivered the VLDL receptor (VLDLR) to the liver of LDLR-deficient mice
and compared the effect of a helper-dependent adenoviral vector with
all viral coding sequences deleted (HD-Ad-mVLDLR) with a
first-generation vector (FG-Ad-mVLDLR), an HD-Ad (HD-Ad-0) that
contained no expression cassette, and dialysis buffer (DB). A single
intravenous injection of HD-Ad-mVLDLR led to a lowering of plasma
cholesterol that lasted 
6 months. Acute liver toxicity (as measured
with liver enzyme elevation) occurred after FG-Ad-mVLDLR but not after
HD-Ad-mVLDLR, HD-Ad-0, or DB treatment. At 6 months, VLDLR was detected
in the liver with Western blotting and with immunofluorescence staining
only in HD-Ad-mVLDLR–treated mice. Aortic atherosclerosis was almost
completely prevented in these animals.
Conclusions—HD-Ad–mediated intravenous delivery of VLDLR to hepatocytes is well tolerated. It produces long-term lowering of plasma cholesterol and prevents atherosclerosis development in LDLR-deficient mice. These data provide support for the feasibility and safety of this approach for therapy of human subjects.
Key Words: genes • adenovirus • receptors • lipoproteins • hypercholesterolemia
This article has been cited by other articles:
 |
|
 |
|
  S. N. Waddington, A. L. Parker, M. Havenga, S. A. Nicklin, S. M. K. Buckley, J. H. McVey, and A. H. Baker Targeting of Adenovirus Serotype 5 (Ad5) and 5/47 Pseudotyped Vectors In Vivo: Fundamental Involvement of Coagulation Factors and Redundancy of CAR Binding by Ad5 J. Virol., September 1, 2007; 81(17): 9568 - 9571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. MacDougall, F. Kramer, P. Polinsky, S. Barnhart, B. Askari, F. Johansson, R. Varon, M. E. Rosenfeld, K. Oka, L. Chan, et al. Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice Am. J. Pathol., June 1, 2006; 168(6): 2064 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Johnson, A. H. Baker, K. Oka, L. Chan, A. C. Newby, C. L. Jackson, and S. J. George Suppression of Atherosclerotic Plaque Progression and Instability by Tissue Inhibitor of Metalloproteinase-2: Involvement of Macrophage Migration and Apoptosis Circulation, May 23, 2006; 113(20): 2435 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Schillinger, S. Y. Tsai, G. E. Taffet, A. K. Reddy, A. J. Marian, M. L. Entman, K. Oka, L. Chan, and B. W. O'Malley Regulatable atrial natriuretic peptide gene therapy for hypertension PNAS, September 27, 2005; 102(39): 13789 - 13794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Merched and L. Chan Absence of p21Waf1/Cip1/Sdi1 Modulates Macrophage Differentiation and Inflammatory Response and Protects Against Atherosclerosis Circulation, December 21, 2004; 110(25): 3830 - 3841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Merched, E. Williams, and L. Chan Macrophage-Specific p53 Expression Plays a Crucial Role in Atherosclerosis Development and Plaque Remodeling Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1608 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Belalcazar, A. Merched, B. Carr, K. Oka, K.-H. Chen, L. Pastore, A. Beaudet, and L. Chan Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia Circulation, June 3, 2003; 107(21): 2726 - 2732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kubo and K. Mitani A New Hybrid System Capable of Efficient Lentiviral Vector Production and Stable Gene Transfer Mediated by a Single Helper-Dependent Adenoviral Vector J. Virol., March 1, 2003; 77(5): 2964 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ng, C. Evelegh, D. Cummings, and F. L. Graham Cre Levels Limit Packaging Signal Excision Efficiency in the Cre/loxP Helper-Dependent Adenoviral Vector System J. Virol., March 27, 2002; 76(9): 4181 - 4189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-H. Kim, A. Jozkowicz, P. A. Piedra, K. Oka, and L. Chan Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector PNAS, October 25, 2001; (2001) 241506298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-H. Kim, A. Jozkowicz, P. A. Piedra, K. Oka, and L. Chan Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector PNAS, November 6, 2001; 98(23): 13282 - 13287. [Abstract] [Full Text] [PDF]
|
|